7 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
inhibitors in CVD ... DECLARE-TIMI 58 - Dapagliflozin ... DAPA-CKD - Dapagliflozin ... DAPA-HF - Dapagliflozin ... visualabstract #table
Cardiovascular and renal effects comparison between SGLT-2 inhibitors
 - Canagliflozin (Invokana)
 - Dapagliflozin (Farxiga)
 - Empagliflozin
comparison between SGLT ... -2 inhibitors - ... Canagliflozin ( ... Invokana) - Dapagliflozin ... (Steglatro) #diabetes
Indications for and pharmacological properties of approved SGLT2 inhibitors

Canagliflozin - Dapagliflozin - Empagliflozin - Ertugliflozin

#SGLT2 #Inhibitors
inhibitors Canagliflozin ... - Dapagliflozin ... - Empagliflozin ... Ertugliflozin #SGLT2 ... #table
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
SGLT2 Inhibitors ... gliflozin): • Empagliflozin ... the three • Dapagliflozin ... • Euglycemic diabetic ... #Summary #DM2 #diabetes
Summary of Diuretic Agents 
Subclass, Drug, Mechanism of Action, Effects, Clinical Applications, Pharmacokinetics, Toxicities, Interaction
CARBONIC ANHYDRASE
Acetazolamide, others SGLT2 ... INHIBITORS • ... Canagliflozin ... • Dapagliflozin, ... Pharmacology #summary #table
SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the
SGLT2 inhibitors ... SGLT2 inhibitors ... treatment of type II diabetes ... (Invokana®), dapagliflozin ... , #dapagliflozin
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... SGLT2 inhibitors ... Improved outcomes in CKD ... #medications #table